Skip to main content
Premium Trial:

Request an Annual Quote

Squibb Licenses Acacia Biosciences' Genome Reporter Matrix

Premium

PRINCETON, NJ--Bristol-Myers Squibb announced it will license the use of Acacia Biosciences' proprietary Genome Reporter Matrix, a technology to identify changes in the expression of thousands of genes in the presence of potential therapeutic compounds. Bristol-Myers Squibb will use the matrix to develop pharmaceutical compound profiles that can help researchers understand the therapeutic benefits and potential side effects of compounds, as well as identify novel targets for drug discovery.

The agreement includes an up-front payment for technology evaluation. Acacia will profile a limited number of potential therapeutic compounds for a fixed fee. Elliott Signal, vice-president of applied genomics for Bristol-Myers Squibb, said Acacia's profiling technology adds to his company's ability to enhance existing therapies and develop novel medicines.

Filed under

The Scan

Could Cost Billions

NBC News reports that the new Alzheimer's disease drug from Biogen could cost Medicare in the US billions of dollars.

Not Quite Sent

The Biden Administration likely won't meet its goal of sending 80 million SARS-CoV-2 vaccine doses abroad by the end of the month, according to the Washington Post.

DTC Regulation Proposals

A new report calls on UK policymakers to review direct-to-consumer genetic testing regulations, the Independent reports.

PNAS Papers on Mosquito MicroRNAs, Acute Kidney Injury, Trichothiodystrophy

In PNAS this week: microRNAs involved in Aedes aegypti reproduction, proximal tubule cell response to kidney injury, and more.